Shanghai Pharmaceutical Group Co., Ltd., which was successfully listed after absorption, merger, capital injection and reorganization, managed Shanghai Xinya Pharmaceutical Co., Ltd. and Shanghai Xinxianfeng Pharmaceutical Co., Ltd., so that the antibiotic business of Xinya Pharmaceutical Co., Ltd. and Xinxianfeng Pharmaceutical Co., Ltd. was organically integrated and became an indispensable and important part of the "whole industrial chain" of the new Shanghai Pharmaceutical Co., Ltd. Looking back on the history of Xinya and the new pioneers, countless China firsts were born under their feet: the earliest national pharmaceutical enterprise in China, the cradle of antibiotics in China, the first penicillin in China, and the first ANDA…… in China. Today, the newly-applied antibiotic professional platform has become one of the largest antibiotic pharmaceutical enterprises in China, and its three brands, namely "Yazi", "Sanhua" and "Four Stars", cover all categories of anti-infective drugs, making it the most complete, abundant and distinctive antibiotic manufacturer in China. Ceftriaxone, cefotaxime, cefoperazone, cefotiam and cefazolin, the company's fist products, rank in the top three in the domestic market, with market share exceeding 2%.

As the first brand product to enter the China market, "four-star brand" cefotiam has the advantage of independent pricing, with a market share of over 35%. The exclusive variety Fengkesong (amphotericin B liposome) fills the domestic blank of liposome technology. More than ten products, such as ceftriaxone, Fengkesong and cefazolin, won the title of famous brand products in Shanghai. Cloxacillin, the raw material drug, and the preparation products of Fengtailing (piperacillin and tazobactam), ceftriaxone, cefotaxime and cefazolin have been successfully registered in Japan, Hong Kong and other four countries and regions.

as a high-tech enterprise in Shanghai, the company adheres to the business philosophy of "quality creates value, innovation creates the future" and takes "science and technology promotes enterprises" as its development purpose, and constantly creates value for society, shareholders, customers, enterprises and employees. The company takes anti-infective drugs as the main development direction, and actively expands the field of anti-tumor drugs, constantly making new breakthroughs in scientific research and innovation. The company's new drug research and development center is a Shanghai-level enterprise technology center, * * * applied for 18 national invention patents, and the number of new products approved by SFDA ranked first in Shanghai, and many heavyweight new products such as ceftizoxime, cefmenoxime, cefotetan and meropenem were introduced one after another. He also undertook three major special projects of new drug creation by the Ministry of Science and Technology.

looking forward to the future, under the background that Shanghai Xinya Pharmaceutical Co., Ltd. is building an industrial park and reorganizing new drugs, Shanghai Xinya Pharmaceutical Co., Ltd. and Shanghai Xinxianfeng Pharmaceutical Co., Ltd. follow the development principle of new drugs, combine the development strategy of new drugs, take Shanghai Xinya Pharmaceutical Co., Ltd. as the main platform, and integrate the high-quality pharmaceutical assets in the antibiotic business sector, making them legal entities with clear corporate governance structure, reasonable main business, strong corporate competitiveness and meeting the requirements of listed companies, and develop into new drugs.